10 Most Oversold Stocks to Buy According to Billionaires

5. Hologic, Inc. (NASDAQ:HOLX)

Number of Billionaire Holdings: 11 

Dollar Value of Billionaire Holdings: $302,755,147 

Hologic, Inc. (NASDAQ:HOLX) is a global medical technology company focused on advancing women’s health through innovative products. It designs and sells medical imaging systems, diagnostic tests, and surgical tools used to detect and treat conditions like breast and cervical cancer.

Hologic, Inc. (NASDAQ:HOLX) reported Q2 2025 revenue of $1.01 billion, a 1.2% year-over-year decline, but still at the upper end of guidance. Non-GAAP EPS remained steady at $1.03, also hitting the high end of guidance. However, the company posted a GAAP net loss of $17.4 million due to non-cash impairment charges, a sharp drop from last year’s $169.9 million profit. Gross margin improved to 61.1%, reflecting better operational efficiency, while operating cash flow remained strong at $169.5 million, with cash reserves totaling $1.43 billion. Despite the earnings dip, HOLX may surface on lists tracking the most oversold stocks amid broader market volatility.

The company’s diagnostics segment continued to lead performance, with revenue up 1.5% (5.2% excluding COVID-related sales), which was driven by molecular diagnostics. Its breast health revenue declined 6.9% amid weaker mammography equipment sales and ongoing market softness. Surgical revenue rose 5.1%, boosted by the Gynesonics acquisition, while skeletal health showed strong growth, up 22.9%.

Hologic, Inc. (NASDAQ:HOLX) reaffirmed its full-year guidance of $4.05–$4.10 billion in revenue and non-GAAP EPS of $4.15–$4.25. Q3 revenue is expected to be between $1.00–$1.01 billion, with EPS of $1.04–$1.07. Despite stock pressure, the company remains attractive to investors due to its solid fundamentals, strong cash flow, continued share buybacks, and growth opportunities in molecular diagnostics and a potential rebound in breast health.